Dose-adjusted concentrations of Posaconazole oral suspension in hematopoietic stem cell transplantation patients and analysis of the influential factors
- VernacularTitle:泊沙康唑口服混悬液在HSCT患者中的剂量校正浓度及其影响因素分析
- Author:
Lin DONG
1
;
Yishuo SHU
2
;
Zhonghua DONG
2
;
Qiaoyan YI
2
;
Hongjuan LI
3
;
Yan GU
3
;
Yan HAN
3
;
Guoyu DING
3
;
Yuqi ZHAO
3
;
Xiaoyue ZHANG
3
;
Xue LI
3
;
Ziyun LIN
3
;
Kai MU
3
;
Yilei YANG
2
;
Haiyan SHI
2
;
Hongmei WANG
3
Author Information
1. Dept. of Hematology，the First Affiliated Hospital of Shandong First Medical University（Shandong Provincial Qianfoshan Hospital），Jinan 250014，China
2. Dept. of Clinical Pharmacy，the First Affiliated Hospital of Shandong First Medical University （Shandong Provincial Qianfoshan Hospital）/Shandong Engineering and Technology Research Center for Pediatric Drug Clinical Evaluation and Development/Shandong Medicine and Health Key Laboratory of Clinical Pharmacy，Jinan 250014，China
3. Dept. of Pediatrics，the First Affiliated Hospital of Shandong First Medical University （Shandong Provincial Qianfoshan Hospital）/Shandong Engineering and Technology Research Center for Pediatric Drug Clinical Evaluation and Development，Jinan 250014，China
- Publication Type:Journal Article
- Keywords:
posaconazole;
dose-adjusted concentration;
influential factor;
hematopoietic stem cell transplantation;
therapeutic
- From:
China Pharmacy
2023;34(24):3025-3029
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To analyze the dose-adjusted concentrations of Posaconazole oral suspension in patients undergoing hematopoietic stem cell transplantation （HSCT） and their influential factors. METHODS Data were collected from hospitalized HSCT patients admitted to the First Affiliated Hospital of Shandong First Medical University （Shandong Provincial Qianfoshan Hospital） from January 2021 to April whtwhm@yeah.net 2023 who took Posaconazole oral suspension for the prevention of invasive fungal disease （IFD） and received blood concentration of posaconazole. The rate of concentration attainment and clinical failure rate of posaconazole for the prevention of IFD were evaluated， and one-way and multiple linear regression analyses were performed for the influential factors of dose-adjusted concentrations （C0/D） of posaconazole. RESULTS A total of 44 patients were enrolled； the mean C0 of posaconazole in patients was （0.99±0.94） µg/mL， and 20 patients had a C0≥0.7 μg/mL， with a concentration attainment rate of 45.45% for the prevention of IFD； 13 cases were clinical failures， with a clinical failure rate of 29.55%. Of 24 patients who did not achieve C0/D of posaconazole for IFD prophylaxis， one patient was a clinical failure despite timely dose adjustment of posaconazole in seven patients； seven of the thirteen patients who did not undergo dose adjustment were clinical failures； and the remaining four patients were switched to other antifungal agents. The results of univariate analysis showed that gender， body mass index （BMI）， renal function， combined use of sodium phenytoin， omeprazole and metoclopramide had a significant effect on the C0/D of posaconazole （P＜0.05）； the results of multivariate linear regression analysis showed that gender， BMI and combined use of sodium phenytoin were the independent factors affecting the C0/D of posaconazole （P＜0.05）. CONCLUSIONS Significant individual differences are reflected in the blood concentration of Posaconazole oral suspension； gender， BMI and combined use of sodium phenytoin are independent factors affecting the C0/D of posaconazole.
